Biosimilar Monoclonal Antibodies Market By Drug Class (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab) By Application and By Region - Global Forecast To 2026
6 October 2017
The global biosimilar monoclonal antibodies market report, offers in-depth insights, revenue details, and other vital information regarding the global biosimilar monoclonal antibodies market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report offers insightful and detailed information regarding the various key players operating in the global market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global biosimilar monoclonal antibodies market report has been segmented on the basis of the compound, product, and region. The global biosimilar monoclonal antibodies market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026.
Antibodies produced by using identical immune cells which are clones of a unique parent cell are referred to as biosimilar monoclonal antibodies. Moreover, since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which they are called biosimilar monoclonal antibodies.
High prevalence rate coupled with increasing incidence of chronic diseases such as cancer and patent expiration on various biological drugs are major factors driving growth of the global market. Also, increasing government investment into development of appropriate healthcare infrastructure especially in developing economies is another factor expected to aid in growth of the global market over the forecast period.
Stringent government regulations for development and distribution of biosimilar monoclonal antibodies is a major factor restraining growth of the global monoclonal antibodies market. Additionally, high costs associated with development of biosimilar monoclonal antibodies is another factor anticipated to hamper growth of the global market over the forecast period.
Patent expirations on biological drugs is expected to create potential opportunities for prominent players in the market to expand their market presence and revenue share.
The global biosimilar monoclonal antibodies market report has been segmented on the basis of drug class, product, and region. On the basis of region, the global biosimilar monoclonal antibodies market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The market in Europe accounted for highest share in the global biosimilar monoclonal antibodies market in terms of revenue, owing to favorable government policies for manufacturing and distribution and high adoption of biosimilar monoclonal antibodies among individuals in countries in the region. The market in Asia Pacific is projected to witness highest growth over the forecast period registering highest CAGR, as compared to that of markets in other regions. This can be attributed to high prevalence rate of chronic diseases and increasing adoption of biosimilar monoclonal antibodies in emerging economies such as China and India.
Market segmentation and key players:
Global biosimilar monoclonal antibodies market segmentation by drug class:
Global biosimilar monoclonal antibodies market segmentation by application:
- Chronic and Autoimmune Diseases
- Growth Hormone Deficiency
- Infectious Diseases
Global biosimilar monoclonal antibodies market segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
- Allergan plc
- Therapeutics SA
- Boehringer Ingelheim GmbH
- Celltrion Inc.
- Coherus BioSciences Inc.
- Dr. Reddy’s Laboratories Ltd.
- Genor BioPharma Co. Ltd.
- Intas Pharmaceuticals Limited
- Novartis AG
- Pfizer Inc.
- Reliance Life Sciences
1.0 Chapter 1
2.0 Chapter 2
2.1 Report Description
2.1.1 Market Definition and Scope
Request for Customization
Don't just take our word. We are trusted by these great companies!